Outsourcing

Pharmaceutical companies and their suppliers share approaches in risk mitigation in sourcing and ways to optimize the outsourced relationship.

The second annual Pharmaceutical Technology Bioprocessing Survey offers a snapshot of the industry following 2009's megamergers.

The author examines the use and advantages of disposable technologies in the fill–finish of sterile pharmaceutical products and how these technologies can reduce costs and time in producing clinical-trial materials.

Merck To Eliminate 15,000 jobs; Tauzin Stepping Down At PhRMA; And More.

RUSNANO, a corporation established by the Russian government to foster the development of nanotechnology, launched a project last week to manufacture targeted-delivery nanodrugs to treat malignant neoplasms.

The Society for Chemical Manufacturers and Affiliates offered its support for a Senate proposal to extend to 2015 current chemical-security standards, the Chemical Facility Anti-Terrorism Standards, which are set to expire this year.

Abbott Completes Acquisition Of Solvay; Merck Names President of Consumer Healthcare; And More.

Margaret Hamburg, commissioner of the US Food and Drug Administration, unveiled a new program to improve the efficiency of import inspections.

VaxGen Shareholders Reject OXiGENE Merger; Roche Creates Research Hub In Singapore; And More.

Cephalon Buys Mepha; BASi's CEO Retires; and More.

Strategic rather than tactical considerations are driving biopharmaceutical outsourcing.

Sharing too much-or too little-information can have disastrous onsequences.

FDA impersonators and counterfeit drugs threaten the public's trust in online pharmacies.

Regulators and industry move to require inspections of API manufacturing facilities.

When it comes to healthcare rform, we must not overlook investment in innovative technologies.

Leading experts share insight on the current and future direction of process analytical technology. This article contains bonus online material.

We never thought implementing complex changes could become more cumbersome.

Novartis CEO To Step Down; DSM To Close Netherlands Facility; And More.

Lonza Group (Basel) plans to reinforce its presence in Asia, including its platform in Nansha, China, and to close its Conshohocken (Riverside), Pennsylvania; Shawinigan, Canada; and Wokingham, United Kingdom, sites in 2010.

FDA Issues Warning Letter To McNeil Healthcare; Charles River Laboratories Will Suspend Operations At Massachusetts Facility.

Bioject Medical Technologies establishes alliance with MPI Research; Biogen Idec CEO to retire; And More.

Grace McNally, in the Office of Compliance at FDA's CDER, discusses the role of QbD and pharmaceutical quality systems as it relates to contract manufacturing.

Team leaders in FDA's Office of Generic Drugs provide an overview.

Plus, novel dosage forms and emerging trends.

From healthcare to corruption to life expectancy, here's what we can learn from the past decade.

Directors and staff miss the mark when it comes to following procedures.

It's customary among columnists to begin a new year with some predictions about what's to come. We don't honour that custom every year, but with what the contract services industry went through in 2009, it seemed appropriate to share thoughts on what we expect for 2010.

BioNanomatrix (Philadelphia) names Edward Erickson president and CEO; and More.

Merck & Co. Acquires Avecia Biologics; Ambrilia Biopharma Closes Manufacturing Facility; And More.

Also, Abbott to acquire Starlims Technologies; GSK Biologicals to form alliance with Intercell.